Chondrocalcinosis secondary to hypomagnesemia in Gitelman's syndrome

Journal of Rheumatology

Volumn 32, Issue 9, 2005, Pages 1840-1842

  Ea, Hang Korng ^a,c   Blanchard, Anne ^b   Dougados, Maxime ^a   Roux, Christian ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c CENTRE VIGGO PETERSEN   (France)

Author keywords

Chondrocalcinosis; Gitelman syndrome; Inorganic pyrophosphate; Magnesium; Na Cl cotransporter; Osteoporosis

Indexed keywords

ALLOPURINOL; CALCIUM PYROPHOSPHATE; COTRANSPORTER; MAGNESIUM; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; SODIUM CHLORIDE COTRANSPORTER; SPIRONOLACTONE; TRIAMTERENE; UNCLASSIFIED DRUG;

ADULT; ARTHRALGIA; ARTICLE; BONE DENSITY; CASE REPORT; CHONDROCALCINOSIS; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; FATIGUE; GENE MUTATION; GITELMAN SYNDROME; HUMAN; HYPOCALCIURIA; HYPOKALEMIA; HYPOMAGNESEMIA; IMAGE ANALYSIS; JOINT EFFUSION; JOINT RADIOGRAPHY; KIDNEY DISTAL TUBULE; KNEE PAIN; MALE; METABOLIC ALKALOSIS; MUSCLE CRAMP; MUSCLE WEAKNESS; MYALGIA; PRIORITY JOURNAL; RECURRENT DISEASE; SYMPTOM; WRIST DISEASE;

BARTTER SYNDROME; BLOOD CHEMICAL ANALYSIS; BONE DENSITY; CHONDROCALCINOSIS; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; MAGNESIUM; MALE; MIDDLE AGED; POTASSIUM; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 24944504330     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Resnick D, Niwayama G. Calcium pyrophosphate dihydrate (CPPD) crystal deposition disease. In: Resnick D, Niwayama G, editors. Diagnosis of bone and joint disorders. Philadelphia: Saunders; 1988:1672-764.
2. Resnick D, Niwayama G, Goergen TG, et al. Clinical, radiographic and pathologic abnormalities in calcium pyrophosphate dihydrate deposition disease (CPPD): pseudogout. Radiology 1977;122:1-15.
3. Timms AE, Zhang Y, Russel RGG, Brown MA. Genetics studies of disorders of calcium crystal deposition. Rheumatology Oxford 2002;41:725-9.
4. Ea H-K, Lioté F. Calcium pyrophosphate dihydrate and basic calcium phosphate crystal-induced arthropathies: Update on pathogenesis, clinical features, and therapy. Curr Rheumatol Rep 2004;6:221-7.
5. Rubenstein J, Pritzker KPH. Crystal-associated arthropathies. AJR Am J Roentgenol 1989;152:685-95.
6. Punzi L, Calo L, Schiavon F, Pianon M, Rosada M, Todesco S. Chondrocalcinosis is a feature of Gitelman's variant of Bartter syndrome: a new look at the hypomagnesemia associated with calcium pyrophosphate dihydrate crystal deposition disease. Rev Rhum Engl Ed 1998;65:571-4.
7. Gitelman HI, Graham JB, Welt LG. A new familial disorder characterized by hypokalemia and hypomagnesemia. Trans Assoc Am Phys 1966;79:221-3.
8. Simon DB, Nelson-Williams C, Bia MJ, et al. Gitelman's variant of Bartter's syndrome, inherited hypokaliemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nature Genet 1996;12:24-30.
9. Schepkens H, Lameire N. Gitelman's syndrome: an overlooked cause of chronic hypokalemia and hypomagnesemia in adults. Acta Clin Belg 2001;56:248-54.
10. Monnens L, Bindels R, Grünfeld JP. Gitelman syndrome comes with age. Nephrol Dial Transplant 1998;13:1617-9.
11. Shaer AJ. Inherited primary renal tubular hypokaliemic alkalosis: a review of Gitelman and Banter syndromes. Am J Med Sci 2001;322:316-32.
12. Cruz DN. The renal tubular Na-Cl co-transporter (NCCT): a potential genetic link between blood pressure and bone density. Nephrol Dial Transplant 2001;16:691-4.
13. Nicolet-Barousse L, Blanchard A, Roux C, et al. Inactivation of Na-Cl co-transporter (NCCT) gene is associated with high bone density through both renal and bone mechanism: analysis of patients with Gitelman syndrome and Ncc null mice. Bone Miner Res 2005;20:799-808.
14. Terkeltaub RA. Inorganic pyrophosphate generation and disposition in pathophysiology. Am J Physiol Cell Physiol 2001;281:C1-11.
15. Ryan LM, Rosenthal AK. Metabolism of extracellular pyrophosphate. Curr Opin Rheumatol 2003;15:311-4.
16. Ho AM, Johnson MD, Kingsley DM. Role of the mouse ANK gene in control of tissue calcification and arthritis. Science 2000; 89:265-270.
17. Netter P, Bardin T, Bainchi A, Richette P, Loeuille D. The ANKH gene and familial calcium pyrophosphate dihydrate deposition disease. Joint Bone Spine 2004;71:365-8.
18. Pendleton A, Johnson MD, Hughes A, et al. Mutations in ANKH cause chondrocalcinosis. Am J Hum Genet 2002;71:933-40.
19. Williams CJ, Zhang Y, Timms A, et al. Autosomal dominant familial calcium pyrophosphate dihydrate deposition disease is caused by mutation in the transmembrane protein ANKH. Am J Hum Genet 2002;71:985-91.
20. 2+ resorption. Science 1999;215:103-6.
21. Ellison DH. Divalent cation transport by the distal nephron: insights from Bartter's and Gitelman's syndromes. Am J Physiol Renal Physiol 2000;279:F616-25.
22. Barry ELR, Gesek FA, Kaplan MR, Hebert SC, Friedman PA. Expression of the sodium-chloride cotransporter in osteoblast-like cells: effect of thiazide diuretics. Am J Physiol 1997;41:C109-16.
23. Hall TJ, Schaueblin M. Hydrochlorothiazide inhibits osteoclastic resorption in vitro. Calcif Tissue Int 1994;55:266-8.